Show simple item record

dc.contributor.authorIbukun, F.I.
dc.date.accessioned2020-04-14T14:28:50Z
dc.date.available2020-04-14T14:28:50Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082818931&doi=10.3390%2fv12040386&partnerID=40&md5=966261079e3ee8ecd23daab830e70215
dc.identifier.urihttp://hdl.handle.net/10713/12549
dc.description.abstractLassa virus (LASV), which causes considerable morbidity and mortality annually, has a high genetic diversity across West Africa. LASV glycoprotein (GP) expresses this diversity, but most LASV vaccine candidates utilize only the Lineage IV LASV Josiah strain GP antigen as an immunogen and homologous challenge with Lineage IV LASV. In addition to the sequence variation amongst the LASV lineages, these lineages are also distinguished in their presentations. Inter-lineage variations within previously mapped B-cell and T-cell LASV GP epitopes and the breadth of protection in LASV vaccine/challenge studies were examined critically. Multiple alignments of the GP primary sequence of strains from each LASV lineage showed that LASV GP has diverging degrees of amino acid conservation within known epitopes among LASV lineages. Conformational B-cell epitopes spanning different sites in GP subunits were less impacted by LASV diversity. LASV GP diversity should influence the approach used for LASV vaccine design. Expression of LASV GP on viral vectors, especially in its prefusion configuration, has shown potential for protective LASV vaccines that can overcome LASV diversity. Advanced vaccine candidates should demonstrate efficacy against all LASV lineages for evidence of a pan-LASV vaccine. Copyright 2020 by the author.en_US
dc.description.urihttps://doi.org/10.3390/v12040386en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofViruses
dc.subjectEpitopesen_US
dc.subjectGlycoproteinen_US
dc.subjectLassa virusen_US
dc.subjectLassa virus diversityen_US
dc.subjectLassa virus vaccineen_US
dc.titleInter-lineage variation of lassa virus glycoprotein epitopes: A challenge to lassa virus vaccine developmenten_US
dc.typeArticleen_US
dc.identifier.doi10.3390/v12040386
dc.identifier.pmid32244402


This item appears in the following Collection(s)

Show simple item record